HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

HUTCHMED (China) LimitedNASDAQ: HCM

Retained Earnings · Q4 FY2025 · quarter ended Dec 2025

Retained earnings remains negative

Q4 FY2025 retained earnings was -$378.64M, compared with -$833.17M a year earlier.

Context

  • Retained earnings amounted to 21.6% of total assets at the end of Q4 FY2025, down 43.8 pp from a year earlier.
  • Retained earnings grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps rising in the next quarterly balance sheet after a +54.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$378.64M— QoQ
Last fiscal yearDec 2025
-$378.64M+54.6% YoY
Year agoDec 2024
-$833.17M+54.6% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+54.6%——
1 year+54.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(378.64M) USD
Year-over-year change
+54.6%

Retained Earnings vs competitors

How HCM compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +54.6% is the 3rd highest of 11, against a peer median of -7.8%.
  • Retained earnings amounts to 21.6% of total assets for HCM, versus a peer median of 81.3%.
HCM Competitors
Retained Earnings for HCM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BNTXBioNTech SEJun 2026€16.6B EUR-9.3%-1.6%81.6%
GMABGenmab A/SJun 2026$4.42B USD+22.9%-34.9%35.3%
INCYIncyte CorporationJun 2026$1.1B USD+316.4%—14.0%
AAPGAscentage Pharma Group InternationalDec 2025CN¥0 CNY+100.0%—0.0%
EXELExelixis, Inc.Jul 2026-$262.53M USD-19.6%—10.5%
HCMHUTCHMED (China) LimitedDec 2025-$378.64M USD+54.6%—21.6%
ANLAdlai Nortye Ltd.Dec 2025-$464.85M USD-8.3%—1350.0%
IDYAIDEAYA Biosciences, Inc.Mar 2026-$835.08M USD-20.2%—81.0%
RCUSArcus Biosciences, Inc.Jun 2026-$1.7B USD-37.0%—184.4%
LEGNLegend Biotech CorporationSep 2026-$1.93B USD-0.0%—114.7%
ZLABZai Lab LimitedJun 2026-$2.73B USD-7.4%—254.0%
Peer median (excluding HCM) —-7.8%-18.2%81.3%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents377.54M313.28M283.59M153.96M71.33M
Short-term Investments634.16M317.72M602.75M682.15M1.3B
Net Receivables147.73M126.72M150.46M167.74M147.83M
Inventory35.76M56.69M50.26M50.4M41.13M
Other Current Assets2.76M3.15M2.68M3.3M2.77M
Total Current Assets1.21B839.89M1.1B1.07B1.57B
Property, Plant & Equipment (Net)66.32M84.67M104.39M97M97.65M
Goodwill3.38M3.14M3.06M2.99M3.11M
Intangible Assets163K3.22M21K08.94M
Long-term Investments(557.68M)(243.94M)48.41M(599.39M)52.25M
Tax Assets9.4M15.37M15.46M012.66M
Other Non-current Assets639M327.1M11.59M707.04M11.15M
Total Non-current Assets160.59M189.56M182.93M207.64M185.76M
Total Assets1.37B1.03B1.28B1.27B1.75B
Account Payables41.18M71.12M36.33M42.52M45.53M
Short-term Debt26.91M3.71M31.16M23.37M27.85M
Tax Payables15.55M1.11M2.58M1.55M0
Deferred Revenue15.55M13.35M57.64M031.42M
Other Current Liabilities40.95M37.39M228.93M290.08M176.94M
Total Current Liabilities311.66M353.9M403.03M376.56M315.78M
Long-term Debt018.1M48.19M59.43M68.19M
Deferred Tax Liabilities2.77M2.71M1.48M2.99M255K
Deferred Revenue (Non-current)(2.77M)190K69.48M48.43M20.13M
Other Non-current Liabilities14.33M12.47M11.35M10.84M95.63M
Total Non-current Liabilities21.49M38.67M133.36M125.78M186.06M
Total Liabilities333.15M392.58M536.39M502.34M501.84M
Common Stock86.45M86.48M87.13M87.16M87.23M
Retained Earnings(610.33M)(971.48M)(870.87M)(833.17M)(378.64M)
Accumulated OCI5.57M(1.9M)(8.16M)(11.59M)(4.53M)
Other Stockholders Equity00000
Minority Interest52.62M26.5M12.85M11.92M13.34M
Total Equity1.04B636.87M743.39M771.85M1.25B
Total Debt38.98M27.01M86.13M89.82M97.89M
Net Debt(338.56M)(286.27M)(197.46M)(64.14M)26.56M

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.